SCHEDULE 13G 0002050902 XXXXXXXX LIVE Common Stock, $0.0001 par value per share 09/18/2025 0001817229 Vor Biopharma Inc. 929033207 500 Boylston Street, Suite 1350 Boston MA 02116 Rule 13d-1(c) ForGrowth III PA B.V. b P7 0 7000000 0 7000000 7000000 N 9.99 OO Forbion Growth Opportunities Fund III Cooperatief U.A. b P7 0 7000000 0 7000000 7000000 N 9.99 OO Forbion Growth III Management B.V. b P7 0 7000000 0 7000000 7000000 N 9.99 OO Vor Biopharma Inc. 500 Boylston Street, Suite 1350, Boston, MA 02116 This statement is being filed by ForGrowth III PA B.V. ("ForGrowth III"), Forbion Growth Opportunities Fund III Cooperatief U.A. ("Forbion Growth III COOP") and Forbion Growth III Management B.V. ("Forbion Growth III"). ForGrowth III, Forbion Growth III COOP and Forbion Growth III are sometimes referred to collectively as the "Reporting Persons". The address of the principal business and principal office of each of the Reporting Persons is c/o Forbion Capital Partners, Gooimeer 2-35, 1411 DC Naarden, The Netherlands. Each of the Reporting Persons is organized under the laws of the Netherlands. Y On June 27, 2025, ForGrowth III acquired pre-funded warrants to purchase up to 7,000,000 shares of the Issuer's Common Stock at an exercise price of $0.002 per share (the "Warrants"). The Warrants became exercisable on September 18, 2025 upon satisfaction of certain material conditions beyond the control of the Reporting Persons. Exercisability of the Warrants is subject to a beneficial ownership limitation of 9.99% of the number of shares of Common Stock to be outstanding immediately after giving effect to the issuance of the shares issuable upon exercise (the "Beneficial Ownership Limitation"). The percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to such Beneficial Ownership Limitation, but the number of shares of Common Stock of the Issuer reported as being issuable upon exercise of the Warrants in Rows 6, 8 and 9 of the cover page for each Reporting Person includes the full number of shares of Common Stock of the underlying the Warrants and does not give effect to the Beneficial Ownership Limitation. As such, some of the Warrants are not presently exercisable due to the Beneficial Ownership Limitation, and the actual number of shares of Common Stock beneficially owned by the Reporting Persons is less than the number of shares of Common Stock of the Issuer reported herein. Forbion Growth III COOP, the sole shareholder of ForGrowth III, and Forbion Growth III, as director of each of ForGrowth III and Forbion Growth III COOP, may be deemed to have voting and investment power over the shares held directly by ForGrowth III. The Reporting Persons may be deemed to beneficially own 9.99% of the outstanding Common Stock of the Issuer after giving effect to the Beneficial Ownership Limitation described in Item 4(a). 0 7,000,000 0 7,000,000 Y Y Y N The Reporting Persons are making this single, joint filing because they may be deemed to constitute a "group" within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Persons disclaim membership in a group and this report shall not be deemed an admission by any of the Reporting Persons that they are or may be members of a "group" for purposes of Rule 13d-5 or for any other purpose. Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. ForGrowth III PA B.V. /s/ V. van Houten and /s/ G.J. Mulder 09/23/2025 Forbion Growth Opportunities Fund III Cooperatief U.A. /s/ V. van Houten and /s/ G.J. Mulder 09/23/2025 Forbion Growth III Management B.V. /s/ V. van Houten and /s/ G.J. Mulder 09/23/2025